Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16335012 | 0.80 | MRGPRX4 (0.47) | IDO1MRGPRX4TDP1L3MBTL1PTGDR2 | |
| SCHEMBL16334881 | 0.79 | IDO1 (0.38) | IDO1NPC1 | |
| SCHEMBL16335177 | 0.75 | MRGPRX4 (0.43) | MRGPRX4PTGDR2MAOB | |
| SCHEMBL16335428 | 0.71 | APLNR (0.33) | PTGDR2MAPTALDH1A1 | |
| SCHEMBL17767297 | 0.71 | MRGPRX4 (0.47) | MRGPRX4PTGDR2MAOB | |
| SCHEMBL17767298 | 0.70 | MRGPRX4 (0.46) | MRGPRX4PTGDR2MAOBNPC1CYP2D6 | |
| SCHEMBL13321691 | 0.66 | MAOB (0.60) | IDO1MRGPRX4MAOB | |
| SCHEMBL18003069 | 0.65 | IDO1 (0.51) | IDO1PTGDR2SLC6A4MAOB | |
| SCHEMBL15613467 | 0.63 | MAOB (0.52) | MAOB | |
| SCHEMBL209289 | 0.63 | CA12 (0.41) | IDO1TDP1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| EP-3013794-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014207071-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | DPM1, CROCC, SNX1 | IDO1 2645/4885MRGPRX4 2298/4885TDP1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.